Nicotinamide mononucleotide ameliorates adriamycin-induced renal damage by epigenetically suppressing the NMN/NAD consumers mediated by Twist2.

Hasegawa K, Sakamaki Y, Tamaki M, Wakino S

Scientific reports12 Aug 2022Cited by 19 (Europe PMC)

PMID35962139PMCIDPMC9374671DOI10.1038/s41598-022-18147-2PepBankPUB-35962139

Summary

The activation of nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylase, Sirt1, after the administration of nicotinamide mononucleotide (NMN) suppresses many diseases. However, the role of NMN and Sirt1 in focal glomerulosclerosis (FSGS) has not yet been elucidated. This study aimed to assess the protective effect of NMN treatment in mice with adriamycin (ADR)-induced FSGS.　Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days. NMN alleviated the increase in urinary albumin excretion in the ADR-treated mice. NMN treatment mitigated glomerulosclerosis and ameliorated the reduced Sirt1 expression and elevated Claudin-1 expression in the kidneys of the mice. Moreover, this treatment improved the decrease in histone methylation and the expression level of Dnmt1 and increased the concentration of NAD⁺ in the kidney. Dnmt1 epigenetically suppressed the expression of the NMN-consuming enzyme nicotinamide mononucleotide adenyltransferase1 (Nmnat1) by methylating the E-box in the promoter region and repressing the NAD-consuming enzyme PARP1. Additionally, NMN downregulated the expression of Nmnat1 in the ADR-treated mice. Short-term NMN treatment in FSGS has epigenetic renal protective effects through the upregulation of Sirt1 and suppression of the NAD and NMN consumers. The present study presents a novel treatment paradigm for FSGS.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In adriamycin-treated mice, NMN alleviated increased urinary albumin excretion.
In plain wordsIn mice treated with adriamycin, NMN reduced the increase in urinary albumin loss.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseUrinary albumin excretion
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
NMN alleviated the increase in urinary albumin excretion in the ADR-treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213901
02AnimalAnimal study (in vivo)Efficacy outcome
In adriamycin-treated mice, NMN mitigated glomerulosclerosis.
In plain wordsIn mice treated with adriamycin, NMN reduced glomerulosclerosis.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseGlomerulosclerosis
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
NMN treatment mitigated glomerulosclerosis and ameliorated the reduced Sirt1 expression and elevated Claudin-1 expression in the kidneys of the mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213902
03AnimalAnimal study (in vivo)Mechanism
In adriamycin-treated mice, NMN ameliorated reduced kidney Sirt1 expression.
In plain wordsIn mice treated with adriamycin, NMN countered the reduction in kidney Sirt1 expression.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseKidney Sirt1 expression
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
NMN treatment mitigated glomerulosclerosis and ameliorated the reduced Sirt1 expression and elevated Claudin-1 expression in the kidneys of the mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213903
04AnimalAnimal study (in vivo)Mechanism
In adriamycin-treated mice, NMN ameliorated elevated kidney Claudin-1 expression.
In plain wordsIn mice treated with adriamycin, NMN reduced elevated kidney Claudin-1 expression.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseKidney Claudin-1 expression
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
NMN treatment mitigated glomerulosclerosis and ameliorated the reduced Sirt1 expression and elevated Claudin-1 expression in the kidneys of the mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213904
05AnimalAnimal study (in vivo)Mechanism
In adriamycin-treated mice, NMN improved the decrease in histone methylation.
In plain wordsIn mice treated with adriamycin, NMN countered the reduction in histone methylation.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseHistone methylation
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Moreover, this treatment improved the decrease in histone methylation and the expression level of Dnmt1 and increased the concentration of NAD⁺ in the kidney.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213905
06AnimalAnimal study (in vivo)Mechanism
In adriamycin-treated mice, NMN improved the decrease in Dnmt1 expression.
In plain wordsIn mice treated with adriamycin, NMN countered the reduction in Dnmt1 expression.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseDnmt1 expression
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Moreover, this treatment improved the decrease in histone methylation and the expression level of Dnmt1 and increased the concentration of NAD⁺ in the kidney.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213906
07AnimalAnimal study (in vivo)Mechanism
In adriamycin-treated mice, NMN increased kidney NAD concentration.
In plain wordsIn mice treated with adriamycin, NMN increased kidney NAD levels.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
IncreaseKidney NAD concentration
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Moreover, this treatment improved the decrease in histone methylation and the expression level of Dnmt1 and increased the concentration of NAD⁺ in the kidney.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213907
08AnimalAnimal study (in vivo)Mechanism
In adriamycin-treated mice, NMN reduced Nmnat1 expression.
In plain wordsIn mice treated with adriamycin, NMN reduced Nmnat1 expression.
Peptide
NMN (nicotinamide mononucleotide)
Outcome
DecreaseNmnat1 expression
Study
mousen: not reported in source
BALB/c mice with adriamycin-induced focal glomerulosclerosis
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 14 consecutive daysAs given in this study (mouse).
Source sentences
Summary
Additionally, NMN downregulated the expression of Nmnat1 in the ADR-treated mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Transient short-term NMN treatment was administered to 8-week-old ADR- or saline-treated BALB/c mice (Cont group) for 14 consecutive days.
Show in the study text Report a problemFND-3596213908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.